Literature DB >> 18031250

Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities.

V J Philbin1, O Levy.   

Abstract

TLR8 (Toll-like receptor 8) is activated by ssRNAs (single-stranded RNAs) and synthetic imidazoquinoline compounds that resemble purines and have immunostimulatory activity. TLR8 agonists are particularly effective at inducing Th1-polarizing responses from human monocytes and myeloid dendritic cells, with the magnitude of response substantially exceeding that induced by agonists of other TLRs. Mechanisms underlying the remarkable efficacy of TLR8 agonists may include: (i) particularly robust activation of intracellular signalling cascades culminating in nuclear translocation of NF-kappaB (nuclear factor kappaB), (ii) activation of BTK (Bruton's tyrosine kinase), and (iii) the ability of some imidazoquinolines to induce TLR-independent effects via antagonism of adenosine receptors. The strong agonist activities of TLR8 agonists also extend to human neonatal leucocytes, which usually display impaired Th1-polarizing responses to many diverse stimuli including agonists of other TLRs. Their strong Th1-polarizing properties render TLR8 agonists attractive targets of biopharmaceutical development as agents that may induce protective immune responses in diverse populations, including newborns.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18031250     DOI: 10.1042/BST0351485

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  22 in total

1.  Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity.

Authors:  Dharmendra Kumar Yadav; Feroz Khan; Arvind Singh Negi
Journal:  J Mol Model       Date:  2011-10-27       Impact factor: 1.810

2.  Development of newborn and infant vaccines.

Authors:  Guzman Sanchez-Schmitz; Ofer Levy
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

Review 3.  Role of innate immunity in neonatal infection.

Authors:  Alex G Cuenca; James L Wynn; Lyle L Moldawer; Ofer Levy
Journal:  Am J Perinatol       Date:  2013-01-07       Impact factor: 1.862

4.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

5.  Development of QSAR model for immunomodulatory activity of natural coumarinolignoids.

Authors:  Dharmendra K Yadav; Abha Meena; Ankit Srivastava; D Chanda; Feroz Khan; S K Chattopadhyay
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

Review 6.  Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis.

Authors:  J L Wynn; J Neu; L L Moldawer; O Levy
Journal:  J Perinatol       Date:  2008-09-04       Impact factor: 2.521

Review 7.  Safety and efficacy of neonatal vaccination.

Authors:  Alicia Demirjian; Ofer Levy
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

8.  Nuclear factor kappaB (NF-kappaB) activation primes cells to a pro-inflammatory polarized response to a Toll-like receptor 7 (TLR7) agonist.

Authors:  Jongdae Lee; Masaaki Hayashi; Jeng-Fan Lo; Colleen Fearns; Wen-Ming Chu; Yunping Luo; Rong Xiang; Tsung-Hsien Chuang
Journal:  Biochem J       Date:  2009-06-26       Impact factor: 3.857

9.  Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Alec R Hermanson; Lauren M Fox; Xinkun Wang; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

Review 10.  Developmental biology of the innate immune response: implications for neonatal and infant vaccine development.

Authors:  Victoria Jane Philbin; Ofer Levy
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.